Stocks Industrials PBSV
OTC · IndustrialsPharma-Bio Serv, Inc. (PBSV)
Pharma-Bio Serv, Inc. brought in $9.5M of revenue over the twelve months to July 31, 2026, up 3.3% from a year earlier. Net income was $251.5K, a net margin of 2.7%. In fiscal 2025 capital spending exceeded operating cash flow by $221.5K. At July 31, 2026 it held $1.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 14, 2026.
Watch PBSV in 60 secondsWhat Pharma-Bio Serv, Inc. does
Pharma-Bio Serv, Inc. is registered with the SEC under industry code SIC 8742 (Services-Management Consulting Services). Its shares trade on OTC under the ticker PBSV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9M | -$100.5K | -$0.00 | -$221.5K |
| 2024 | $9.5M | -$777.6K | -$0.03 | -$726.4K |
| 2023 | $17M | $1.3M | $0.06 | $1.9M |
| 2022 | $19.4M | $1M | n/a | $573.2K |
| 2021 | $20.1M | -$2.1M | n/a | $794K |
| 2020 | $21.6M | $2.1M | $0.09 | $1.5M |
Full financial statements: income, balance sheet and cash flow
Where PBSV ranks in Industrials
Dividends
It paid out $1.7M in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2025 | n/a | $1.7M | n/a |
| 2024 | n/a | $1.7M | n/a |
| 2023 | n/a | $1.7M | 132% |
| 2022 | n/a | $3.4M | 342% |
| 2021 | n/a | $1.7M | n/a |
| 2020 | n/a | $1.7M | 84% |
Latest SEC filings
What Pharma-Bio Serv, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- September 14, 2026Quarterly report 10-Q · period to July 31, 2026Revenue rose 19% to $2.3M versus the same quarter last year; diluted EPS -$0.00 versus -$0.01.
- June 15, 2026
- June 15, 2026Quarterly report 10-Q · period to April 30, 2026Revenue rose 12% to $2.7M versus the same quarter last year; diluted EPS $0.01 versus $0.00.
- May 15, 2026
- April 16, 2026
- April 16, 2026Proxy statement DEF 14A
- March 17, 2026
- March 17, 2026Quarterly report 10-Q · period to January 31, 2026Revenue fell 7.1% to $2.3M versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- February 27, 2026Annual report (amended) 10-K/A · period to October 31, 2025Revenue fell 5.3% to $9M versus the prior year; diluted EPS -$0.00 versus -$0.03.
Insider trades
What the people running Pharma-Bio Serv, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 9, 2026 | Spindel HowardDirector | Other changeindirect | 42,504 | - |
Questions about PBSV
What does Pharma-Bio Serv, Inc. do?
Pharma-Bio Serv, Inc. is registered with the SEC under industry code SIC 8742 (Services-Management Consulting Services). Its shares trade on OTC under the ticker PBSV.
Is Pharma-Bio Serv, Inc. profitable?
Yes. Over the twelve months to July 31, 2026 it reported net income of $251.5K on revenue of $9.5M, a net margin of 2.7%.
How much revenue does Pharma-Bio Serv, Inc. make?
Over the twelve months to July 31, 2026 Pharma-Bio Serv, Inc. reported revenue of $9.5M. That is 3.3% more than a year earlier.
When did Pharma-Bio Serv, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 14, 2026. It covers the period to July 31, 2026.
Similar companies
Compare PBSV with
Follow PBSV
Get an email when Pharma-Bio Serv, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow PBSV: get an email when it filesWhere the numbers come from
Financial figures are the values Pharma-Bio Serv, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.